Diligence memo · auto-generated · as of July 2, 2026
ImmPACT Bio USA Inc.
ImmPACT Bio USA Inc. looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
ImmPACT Bio USA Inc. operates in Biotechnology, based in West Hills.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
ImmPACT Bio USA Inc. has raised $144M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series D+ (a $100M–$400M round).
Largest single filing: $140M on 2022-01-14.
Most recent recorded round closed around 2022-01-14.
Valuation (modeled)modeled
Provath models ImmPACT Bio USA Inc. at approximately $3.5B (range $634M–$6.4B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 1.72× the median modeled value of Series D+ Biotechnology companies in 2022–2024 (75 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 9 months.
Last raise 4.5 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 1.3× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 94% of Biotechnology peers (4293 compared).
Modeled value ranks above 98% of those peers.
Closest niche peers: Areteia Therapeutics, Inc., GIO World Health Ltd, Crinetics Pharmaceuticals, Inc., 2seventy bio, Inc., Gio World Health (Europe) Sa.
Peoplefiled
15 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.